RNA
Price:
$31.35
Market Cap:
$3.74B
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.[Read more]
Industry
Biotechnology
IPO Date
2020-06-12
Stock Exchange
NASDAQ
Ticker
RNA
According to Avidity Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 3.38B. This represents a change of 17.45% compared to the average of 2.88B of the last 4 quarters.
The mean historical Enterprise Value of Avidity Biosciences, Inc. over the last ten years is 617.36M. The current 3.38B Enterprise Value has changed 54.61% with respect to the historical average. Over the past ten years (40 quarters), RNA's Enterprise Value was at its highest in in the September 2024 quarter at 5.30B. The Enterprise Value was at its lowest in in the June 2020 quarter at -109126640.00.
Average
617.36M
Median
592.92M
Minimum
225.64M
Maximum
979.42M
Discovering the peaks and valleys of Avidity Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 161.11%
Maximum Annual Enterprise Value = 979.42M
Minimum Annual Increase = -76.96%
Minimum Annual Enterprise Value = 225.64M
Year | Enterprise Value | Change |
---|---|---|
2023 | 485.53M | -41.34% |
2022 | 827.77M | 40.50% |
2021 | 589.16M | 161.11% |
2020 | 225.64M | -76.96% |
2019 | 979.42M | 64.15% |
The current Enterprise Value of Avidity Biosciences, Inc. (RNA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
634.15M
5-year avg
621.50M
10-year avg
617.36M
Avidity Biosciences, Inc.’s Enterprise Value is greater than TCR2 Therapeutics Inc. (79.12M), less than Revolution Medicines, Inc. (7.98B), greater than Black Diamond Therapeutics, Inc. (123.50M), greater than Atreca, Inc. (-8620212.00), greater than Passage Bio, Inc. (33.76M), greater than Akero Therapeutics, Inc. (1.71B), greater than Protagonist Therapeutics, Inc. (2.22B), greater than Stoke Therapeutics, Inc. (451.87M), greater than IGM Biosciences, Inc. (383.55M), less than Cerevel Therapeutics Holdings, Inc. (8.24B), greater than Cullinan Oncology, Inc. (614.81M), greater than Mineralys Therapeutics, Inc. (539.76M), greater than Day One Biopharmaceuticals, Inc. (857.57M), greater than SpringWorks Therapeutics, Inc. (2.66B), greater than Relay Therapeutics, Inc. (605.49M), greater than Pliant Therapeutics, Inc. (801.51M), greater than Arvinas, Inc. (1.20B),
Company | Enterprise Value | Market cap |
---|---|---|
79.12M | $58.11M | |
7.98B | $8.09B | |
123.50M | $123.92M | |
-8620212.00 | $3.57M | |
33.76M | $40.24M | |
1.71B | $1.99B | |
2.22B | $2.34B | |
451.87M | $599.59M | |
383.55M | $380.57M | |
8.24B | $8.19B | |
614.81M | $714.45M | |
539.76M | $637.04M | |
857.57M | $1.28B | |
2.66B | $2.74B | |
605.49M | $708.03M | |
801.51M | $820.92M | |
1.20B | $1.29B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Avidity Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Avidity Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Avidity Biosciences, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Avidity Biosciences, Inc. (RNA)?
What is the 3-year average Enterprise Value for Avidity Biosciences, Inc. (RNA)?
What is the 5-year average Enterprise Value for Avidity Biosciences, Inc. (RNA)?
How does the current Enterprise Value for Avidity Biosciences, Inc. (RNA) compare to its historical average?